Tuesday, 17 November 2026European Markets

VIVORYON Stock Was Up By 12.5% Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with VIVORYON (VVY.AS) rising 12.5% to €0.51 on Monday while AEX-Index jumped 0.76% to €866.51.

About VIVORYON

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

Volume

Today's last reported volume for VIVORYON is 301172 which is 49.65% below its average volume of 598184.

Volatility

VIVORYON's last week, last month's, and last quarter's current intraday variation average was a negative 1.49%, a negative 1.05%, and a positive 3.70%.

VIVORYON's highest amplitude of average volatility was 7.24% (last week), 3.03% (last month), and 3.70% (last quarter).

More news about VIVORYON (VVY.AS).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 22 Apr 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›